Macular Edema Pipeline Guide 2021: Drugs in Development –

Macular Edema Pipeline Guide 2021: Drugs in Development –

Macular Edema Pipeline Guide 2021: Drugs in Development –

DUBLIN–(BUSINESS WIRE)–The “Macular Edema (Ophthalmology) – Drugs in Development, 2021” report has been added to’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 4, 2, 3, 9 and 1 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Companies Mentioned

  • 3SBio Inc
  • Aerie Pharmaceuticals Inc
  • Anew Oncology Inc
  • AsclepiX Therapeutics Inc
  • Celon Pharma SA
  • Clearside BioMedical Inc
  • F. Hoffmann-La Roche Ltd
  • Huadong Medicine Co Ltd
  • Luye Pharma Group Ltd
  • Mabion SA
  • Novartis AG
  • PharmAbcine Inc
  • Polus Inc
  • Prestige BioPharma Ltd
  • Profarma
  • Sustained Nano Systems LLC
  • Taiwan Liposome Co Ltd
  • Targeted Therapy Technologies LLC
  • Tarsius Pharma Ltd
  • Tiantai Yinkang Biological Medicine Co Ltd
  • Xbrane Biopharma AB

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900